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ARF is a key activator of p53, and together they form a critical duo for protection against cancer. Previous
evidence had recognized the regulatory potential of ubiquitin-mediated degradation of ARF. The recent
identification of TRIP12/ULF as a ubiquitin ligase of ARF adds an important missing piece to the ARF/p53
pathway.The ARF-mediated activation of tumor
suppressor p53 in response to oncogene
activation is a major determinant of
protection against cancer. In normal cells,
p53 activity is dampened by the action of
Mdm2, an E3 ubiquitin ligase that targets
p53 for proteasomal degradation. ARF
binds to Mdm2 and inhibits its action on
p53, thus efficiently promoting the accu-
mulation of p53 and the implementation
of a defensive response in the formof apo-
ptosis or cell-cycle arrest (Junttila and
Evan, 2009). A variety of oncogenes are
able to elicit the activation of ARF, most
notably Myc overexpression and onco-
genic mutant Ras, and absence of ARF
in mice severely impairs the tumor sup-
pressive activity of p53 (Junttila and
Evan, 2009). A number of transcriptional
modulators have been found to mediate
the induction of ARF upon oncogene acti-
vation (Kim and Sharpless, 2006). The
extensively reported role of transcription
in determining the levels of ARF has had,
however, the adverse effect of overlook-
ing the regulatory potential of ARF protein
stability.
ARF and INK4a form a famous odd
couple not only for their potent tumor
suppressor activity but also for their intri-
cate connections: they are encoded by
the same CDKN2A genomic locus and
share their last two exons, yet the
common exons are translated from
different reading frames and they have
disparate amino acid sequences (Kim
and Sharpless, 2006). Still, there is some-
thing they share about their amino acid
composition that make the couple even
more unique: they are 2 of the only about
15 proteins encoded by the human ge-
nome that completely lack lysine residues
(Ben-Saadon et al., 2004). Interestingly,
lysine-less proteins can be ubiquitylated
at their N-terminus through what is knownas N-terminal ubiquitylation or theUbiqui-
tin Fusion Degradation (UFD) pathway
(Ciechanover and Ben-Saadon, 2004).
The UFD pathway, although not exclusive
for lysine-less proteins, is the only avail-
able choice for ubiquitin-proteasome de-
gradation in the case of lysine-less pro-
teins. This is indeed the case of ARF and
INK4a, as respectively reported by the
laboratories of Chuck Sherr (Kuo et al.,
2004) and Aaron Ciechanover (Ben-Saa-
don et al., 2004). These observations left
in the air the obvious question of identi-
fying the E3 ubiquitin ligase responsible
for the N-terminal ubiquitylation of ARF,
of INK4a, or, for that matter, of any E3
ubiquitin ligase involved in UFD given
that none was known in mammalian cells.
The above gives way to a different
chapter of the story that has its roots in
yeast, where the UFD pathway had been
dissected long ago and UFD4 had been
identified as a key E3 enzyme in the
pathway (Johnson et al., 1995). It was not
until very recently that the team led by
Jong-Bok Yoon noticed sequence simi-
larity between yeast UFD4 and a human
protein known as TRIP12, and went on to
demonstrate that TRIP12 is a bona fide
E3 ubiquitin ligase for the mammalian
UFD pathway (Park et al., 2009). TRIP12
had been previously identified, but not
characterized, among a series of proteins
interacting with the thyroid hormone re-
ceptor, hence its name Thyroid hormone
Receptor Interacting Protein 12 (Lee
et al., 1995). The identification of TRIP12
as an E3 enzyme of the UFD pathway
and the existence of ARF degradation
through this pathway set the stage for
the next chapter in this fascinating story.
One of the few instances in which ARF
protein stability has been carefully studied
is in relation to nucleophosmin (NPM).
NPM is a major component of the nucle-Cancer Celolus with important functions regulating
cell growth, proliferation, and transforma-
tion, plus additional important effect of
stabilizing ARF protein levels (Grisendi
et al., 2006). Based on this, Wei Gu and
coworkers analyzed, by mass spectrom-
etry, the protein complexes bound to
NPM. From a simplistic point of view,
the initial expectation would be to find
proteins that contribute to stabilize ARF.
Instead, the authors found TRIP12 and
demonstrated that TRIP12 served as an
E3 ubiquitin ligase for the degradation of
ARF. On this basis, they renamed this
protein ULF, for Ubiquitin Ligase for ARF
(Chen et al., 2010). To test the functional
consequences of TRIP12/ULF, the
authors downregulated the protein with
RNAi and examined the effect on p53
and cell proliferation. In support of a rele-
vant role of TRIP12/ULF in ARF function,
knockdown of TRIP12/ULF resulted in
increased stability of ARF, accompanied
by accumulation of p53 and cell-cycle
arrest. All these functional consequences
were dependent on the presence of ARF,
since concomitant RNAi knockdown of
ARF abolished the increased levels of
p53 and allowed the cells to proliferate
normally (Chen et al., 2010). Of note, no
effects were observed on INK4a levels
upon inhibition of TRIP12/ULF, suggest-
ing that INK4a may have a different E3
ubiquitin ligase for its degradation.
To further extend the above observa-
tions, the authors examined the interplay
between TRIP12/ULF and two known
positive regulators of ARF, namely, NPM
and Myc. In the case of NPM, the authors
conclude thatNPMpromotes thestabiliza-
tion of ARF by retaining ARF in nucleoli,
thus away from the action of TRIP12/
ULF, which resides mainly in the nucleo-
plasm (Figure 1). In the case of Myc, the
study of TRIP12/ULF also brings new andl 17, April 13, 2010 ª2010 Elsevier Inc. 317
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Figure 1. A New Addition to the ARF/p53 Pathway
A recent report (Chen et al., 2010) has identified TRIP12/ULF as a key E3
ubiquitin ligase that adds ubiquitin to ARF (Ub-Lig) and induces its degrada-
tion. ARF is protected from TRIP12/ULF when bound to NPM and localized
in the nucleolus. Moreover, in the nucleolus, ARF binds and inhibits Mdm2,
which, in turn, is the main E3 ubiquitin ligase of p53.
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shown that Myc activates
ARF through transcriptional
upregulation of its mRNA
levels (Zindy et al., 1998).
However, this does not seem
to be the whole story to Myc
and ARF. Wei Gu and
coworkers found that Myc
inhibits TRIP12/ULF ubiquitin
ligase activity toward ARF
(Chen et al., 2010). This effect
was shown to be dependent
on direct Myc-TRIP12/ULF
interaction and does not
require the transcriptional
activity of Myc (Figure 1).
Consequently, a transcription-
ally deficient Myc protein can
increase the half-life of ARF
and thus increase the levels
of p53 and its target p21
(Chen et al., 2010).
These data raise the possi-
bility that TRIP12/ULF could
be a novel sensor of onco-
genic stress upstream of
ARF. In this regard, it will beinteresting to know how TRIP12/ULF
activity is regulated when normal cells
are challenged by oncogenic stress.
Also, TRIP12/ULF might have pro-onco-
genic activity if deregulated, since
unchecked TRIP12/ULF activity will
promote degradation of ARF, rendering318 Cancer Cell 17, April 13, 2010 ª2010 Elscells unprotected from oncogenic stress.
If this were the case, targeting TRIP12/
ULF activity with small drug inhibitors
might offer a novel strategy for thera-
peutic intervention of cancer, thus
following the footsteps of agents such as
Nutlin3a that targets Mdm2.evier Inc.REFERENCES
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